Clinical trials related to new indications of capmatinib (Touradida) and future prospects

Capmatinib (capmatinib) is a selective METtyrosine kinase inhibitor initially indicated for the treatment of patients with METexon 14 skipping mutations in advanced non-small cell lung cancer (NSCLC). In recent years, with the deepening of research on the mechanism of the MET pathway in various solid tumors, the exploration of new indications for capmatinib has gradually become the focus of clinical research. Multiple clinical trials are evaluating its efficacy in other MET driven tumor types, such as gastric cancer, hepatocellular carcinoma and certain patients with MET amplified breast cancer, laying the foundation for future expansion of indications.

In early clinical studies, capmatinib showed certain anti-tumor activity in patients with MET amplified gastric cancer. Some phase II clinical trial results show that for patients with gastric cancer whose MET gene is amplified or overexpressed, capmatinib combined with chemotherapy or monotherapy can induce partial remission or disease stabilization. This finding suggests that capmatinib may play a role in the personalized treatment of gastrointestinal tumors, providing a scientific basis for the application of MET targeted therapy in the field of gastric cancer.

In addition, initial progress has been made in the exploration of capmatinib in hepatocellular carcinoma and breast cancer. For patients with hepatocellular carcinoma who have MET overexpression or amplification, some early trials have shown that capmatinib can improve the disease control rate and extend the median progression-free survival while being safe and controllable. Among breast cancer patients, subgroup studies targeting high expression of MET have also shown certain efficacy, providing potential for precision treatment of multiple cancer types in the future.

In terms of future prospects, the expansion of the indications of capmatinib still requires larger-scale, multi-center Phase III clinical trials to verify the efficacy and safety. At the same time, research on combination immunotherapy or other targeted drugs is ongoing in order to improve the response rate and prolong survival. With the maturity of biomarker screening and personalized treatment strategies, capmatinib is expected to become a key targeted drug for a variety of MET-driven tumors, providing patients with more precise and efficient treatment options.

Reference materials:https://www.drugs.com/